VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2019 | Current affairs: opinion on quizartinib approval status in AML

Mark Levis, MD, PhD, from the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the current status of quizartinib monotherapy for FLT3+ relapsed/refractory acute myeloid leukemia (AML) following the results of the QuANTUM-R trial (NCT02039726). He also expresses his excitement about the devlopment of the QuANTUM-First trial (NCT02668653). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter